Le Lézard
Classified in: Health
Subject: MRR

World Home Healthcare Technology Innovations and Growth Analysis Report 2022: Emergence of Home Healthcare as a Promising Substitute to In-hospital Care


Dublin, Oct. 5, 2022 /PRNewswire/ -- The "Home Healthcare Technology Innovations and Growth Opportunities" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

This growth opportunity-technology (GO-TE) study highlights innovation in home healthcare technologies, including home care ventilators, home dialysis devices, at-home electrocardiograms, and home infusion devices.

The market scope of this GO-TE study is global. It studies some of the pathbreaking innovators in this space and their technology readiness levels.

Hospitals have been the mainstay of providing care delivery to patients, including diagnostic services and therapeutic interventions. However, as a limited number of health professionals cater to multiple patients, caregivers are unable to dedicate sufficient time to each patient to understand their needs and effectively monitor their response to the treatment delivered to them, which impacts health outcomes. Furthermore, in-hospital care exposes patients to HAIs that can impact their well-being and cause a spike in the mortality rate.

These limitations have necessitated the demand for home healthcare that provides greater convenience to patients and improves their health outcomes and reduces healthcare costs for providers.

Typically, home healthcare involves medical care provided by physicians and other skilled medical professionals to patients outside the traditional healthcare environment (including hospitals) in the comfort of their homes.

As home healthcare offers hospital-level diagnostic and treatment services to patients, mainly to address critical pain points such as reducing the incidence of hospital-acquired infections (HAIs), decreasing preventable hospital readmissions, and enabling effective care for patients, the model is attracting healthcare providers.

Key Topics Covered:

1. Strategic Imperatives

2. Growth Opportunity Analysis

3. Home Care Ventilators

4. At-home ECG Devices

5. Home Dialysis Devices

6. Home Infusion Devices

7. Assessment of Industry Trends

8. Growth Opportunity Universe

9. Next Steps

For more information about this report visit https://www.researchandmarkets.com/r/5kibn9

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

at 00:29
Cadence Education, LLC. ("Cadence Education"), one of the largest providers of early childhood education in North America, announced that its 2022 annual company-wide fundraising St. Jude Trike-A-Thon event has raised $330,145. This brings Cadence...

at 00:00
This webinar will enable attendees to understand and comply with the FDA's cell and gene therapy...

30 nov 2022
IVERIC bio, Inc. (the "Company"), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions. In addition,...

30 nov 2022
CNS Pharmaceuticals, Inc. ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing of a public...

30 nov 2022
Aura Biosciences, Inc. ("Aura") , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of...

30 nov 2022
Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") , a publicly traded special purpose acquisition company ("SPAC") formed for the...



News published on 5 october 2022 at 07:30 and distributed by: